image credit: Unsplash

FDA delays decision on Moderna’s COVID-19 vaccine in 12-17 age group because of myocarditis concerns: WSJ

October 18, 2021


After reports in four Nordic countries of the heart inflammation condition myocarditis, the FDA has delayed a decision on the Moderna COVID-19 shot for kids between the ages of 12 to 17, The Wall Street Journal reports.

This month the shot was closing in on a nod, the newspaper reports, but now officials are taking a closer look at the vaccine’s safety profile.

The move comes after four countries—Denmark, Finland, Norway and Sweden—recommended against use of the Moderna shot by those under the age of 30. Some countries have said that young people should instead get the Pfizer vaccine.

Read More on FiercePharma